Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: An open study of 31/2 years duration

International Journal of Geriatric Psychiatry

Volumn 25, Issue 4, 2010, Pages 411-418

  Ritchie, C W ^a   Harrigan, S ^b   Mastwyk, M ^c   Macfarlane, S ^c   Cheesman, N ^a   Ames, D ^b,d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Caulfield Hospital   (Australia)

^d NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

Author keywords

Adherence; Antipsychotic; Clinical trial; Elderly; Olanzapine; Risperidone; Schizophrenia; Survival analysis

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; OLANZAPINE; RISPERIDONE;

AGED; ARTICLE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; FEMALE; FOLLOW UP; GERONTOPSYCHIATRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; OPEN STUDY; PATIENT COMPLIANCE; PREDICTOR VARIABLE; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT;

AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISPERIDONE; SCHIZOPHRENIA;

EID: 77949498638     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2354     Document Type: Article

References (21)

1. Arunpongpaisal S, Ahmed I, Aqeel N, Paholpak S. 2003. Antipsychotic drug treatment for elderly people with late-onset schizophrenia. Cochrane Database Systematic Reviews (2) CD004162.
2. Ascher-Svanum H, Zhu B, Faries D, et al. 2006. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatr 6: 8.
3. Cooper D, Moisan J, Gaudet M, Abdous B, Grégoire JP. 2005. Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia. Can J Psychiatr 50: 901-907.
4. Cooper D, Moisan J, Grégoire JP. 2007. Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatr 68(6): 818-825.
5. Fenton WS, Blyler CR, Heinssen RK. 1997. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 23: 153-162.
6. Jeste DV, Dolder CR, Nayak GV, Salzman C. 2005. Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature. Harv Rev Psychiatr 13: 340-351.
7. Kilzieh N, Todd-Stenberg JA, Kennedy A, Wood AE, Tapp AM. 2008. Time to discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting. J Clin Psychopharmacol 28(1): 74-77.
8. Lieberman JA, Stroup TS, McEvoy JP. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 353: 1209-1223.
9. Mitchell AJ, Selmes T. 2007. Why don't patients take their medicine? Reasons and solutions in psychiatry. Adv Psychiatr Treat 13: 336-346.
10. Overall JE, Gorham DR. 1962. The brief psychiatric rating scale. Psychol Rep 10: 799-812.
11. Pelagotti F, Santarlasci B, Vacca F, Trippoli S, Messori A. 2003. Dropout rates with olanzapine or risperidone: a multi centre observational study. Eur J Clin Pharmacol 59: 905-909.
12. Ritchie CW, Chiu E, Harrigan S, et al. 2003. The impact upon extrapyramidal side-effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psychiatr 18: 432-440.
13. Ritchie CW. 2005. The use of antipsychotic medication for schizophrenia occurring in late life. In Psychosis in the Elderly, Hassett A, Ames D, Chiu E (eds). Taylor and Francis: Abingdon; pp. 71-83.
14. Ritchie CW, Chiu E, Harrigan S, et al. 2006. A comparison of efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration. Int J Geriatr Psychiatr 21: 171-179.
15. Rittmannsberger H, Pachinger T, Keppelmüller P, Wancata J. 2004. Medication adherence among psychotic patients before admission to inpatient treatment. Psychiatr Serv 55: 174-179.
16. Sajatovic M, Blow FC, Kales HC, et al. 2007. Age comparison of treatment adherence with antipsychotic medications among individuals with bipolar disorder. Int J Geriatr Psychiatr 22(10): 992-998.
17. Sapra M, Vahia I, Reyes P, Ramirez P, Cohen C. 2008. Subjective reasons for adherence to psychotropic medication and associated factors among older adults with schizophrenia. Schizophr Res 106(2-3): 348-355.
18. Simpson GM, Angus JW. 1970. A rating scale for extra-pyramidal sideeffects. Acta Psychiatr Scand 212 (Suppl): 11-19.
19. Stephen RM. 2003. Overview of partial compliance. J Clin Psychiatr 64: 3-9.
20. Streiner DL. 1995. Stayin' alive: an introduction to survival analysis. Can J Psychiatr 40: 439-444.
21. Sullivan G, Wells KB, Morgenstern H, Leake B. 1995. Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi. Am J Psychiatry 152: 1749-1756.